Hepatitis C New Drugs Review
27.7K views | +9 today
Follow
 
Scooped by Krishan Maggon
onto Hepatitis C New Drugs Review
Scoop.it!

Gilead Sciences, Inc. (GILD) CEO Discusses Q2 2013 Results

Gilead Sciences, Inc. (GILD) CEO Discusses Q2 2013 Results - Earnings Call ...
more...
No comment yet.
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval" | Hepatitis C New Drugs Review | Scoop.it
Krishan Maggon published version 121 of a knol titled: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"...
more...
Scooped by Krishan Maggon
Scoop.it!

Impact of IFNL4-∆G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals

Impact of IFNL4-∆G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals | Hepatitis C New Drugs Review | Scoop.it
In direct acting antiviral (DAA)-treated HCV genotype 1, the sustained virologic response
rate with the ∆G/∆G genotype of IFNL4 rs368234815 (86.8%) was significantly lower
than with ∆G/TT (95.9%, p=0.03) or TT/TT (98.6%, p=0.01). The SVR odds ratio for ∆G/∆G
compared to TT/TT was 0.10 (p=0.03). IFNL4 genotype might predict DAA-response.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New drug for hepatitis C is 97% effective

New drug for hepatitis C is 97% effective | Hepatitis C New Drugs Review | Scoop.it
Combination of ravidasvir with already known drugs has shown to be 97% effective for hepatitis C treatment.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

12 weeks of a Ribavirin‐free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation - Houssel‐Debry - - Hepatology - Wiley Online Library

Sofosbuvir (SOF) combined with NS5A inhibitors has demonstrated its efficacy in treating a recurrence of HCV after liver transplantation. However, the duration of treatment and the need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether liver transplant recipients could be treated with an SOF+NS5A inhibitor‐based regimen without RBV for 12 weeks after liver transplantation (LT). Methods: Between October 2013 and December 2015, 699 LT recipients experiencing an HCV recurrence were enrolled in the multicentre ANRS CO23 CUPILT cohort. We selected patients receiving SOF and NS5A inhibitor +/‐ RBV and followed for at least 12 weeks after treatment discontinuation. The primary efficacy endpoint was a SVR12. Results: Among these 699 patients, 512 fulfilled the inclusion criteria. Their main characteristics were: 70.1% genotype 1, 18.2% genotype 3, 21.1% cirrhosis and 34.4% previously treated patients. We identified four groups of patients according to their treatment and duration: SOF+NS5A without RBV for 12 (156 patients) or 24 (239 patients) weeks; SOF+NS5A+RBV for 12 (47 patients) or 24 (70 patients) weeks. SVR12 values reached 94.9%, 97.9%, 95.7% and 92.9%, respectively (p=0.14). Only twenty patients experienced a treatment failure. Under multivariate analysis, factors such as fibrosis stage, previous treatment, HCV genotype and baseline HCV viral load did not influence the SVR12 rates in the four groups (p=0.21). Haematological adverse events were more common in the RBV group: anaemia (p<0.0001), blood transfusion (p=0.0001). Conclusion: SOF+NS5A inhibitors without RBV for 12 weeks constituted reliable therapy for recurrent HCV after liver transplantation with an excellent SVR 12 whatever the fibrosis stage, HCV genotype and previous HCV treatment. This article is protected by copyright. All rights reserved.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The telomerase enzyme and liver renewal

The telomerase enzyme and liver renewal | Hepatitis C New Drugs Review | Scoop.it
Cell-tracing analysis reveals that a disperse group of cells in the mouse liver express the enzyme telomerase, which preserves chromosome ends. These cells contribute to liver maintenance and regeneration.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide | Journal of Nanobiotechnology

Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide | Journal of Nanobiotechnology | Hepatitis C New Drugs Review | Scoop.it
Virus-like-particles (VLPs) are attractive nanoparticulate scaffolds for broad applications in material/biological sciences and medicine. Prior their functionalization, specific adaptations have to be carried out. These adjustments frequently lead to disordered particles, but the particle integrity is an essential factor for the VLP suitability. Therefore, major requirements for particle stabilization exist. The objective of this study was to evaluate novel stabilizing elements for functionalized chimeric hepatitis B virus core antigen virus-like particles (HBcAg-VLP), with beneficial characteristics for vaccine development, imaging or delivery. The effects of a carboxy-terminal polyhistidine-peptide and an intradimer disulfide-bridge on the stability of preclinically approved chimeric HBcAg-VLPs were assessed. We purified recombinant chimeric HBcAg-VLPs bearing different modified C-termini and compared their physical and chemical particle stability by quantitative protein-biochemical and biophysical techniques. We observed lower chemical resistance of T = 3- compared to T = 4-VLP (triangulation number) capsids and profound impairment of accessibility of hexahistidine-peptides in assembled VLPs. Histidines attached to the C-terminus were associated with superior mechanical and/or chemical particle stability depending on the number of histidine moieties. A molecular modeling approach based on cryo-electron microscopy and biolayer interferometry revealed the underlying structural mechanism for the strengthening of the integrity of VLPs. Interactions triggering capsid stabilization occur on a highly conserved residue on the basis of HBcAg-monomers as well as on hexahistidine-peptides of adjacent monomers. This new stabilization mechanism appears to mimic an evolutionary conserved stabilization concept for hepadnavirus core proteins. These findings establish the genetically simply transferable C-terminal polyhistidine-peptide as a general stabilizing element for chimeric HBcAg-VLPs to increase their suitability.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Insufficiency of DNA repair enzyme ATM promotes naive CD4 T-cell loss in chronic hepatitis C virus infection

Insufficiency of DNA repair enzyme ATM promotes naive CD4 T-cell loss in chronic hepatitis C virus infection | Hepatitis C New Drugs Review | Scoop.it

Our results demonstrate that insufficient DNA repair enzyme ATM leads to increased DNA damage and renders HCV T cells prone to apoptotic death, which contribute to the loss of naive T cells in HCV infection. Our study reveals a novel mechanism for T-cell dysregulation and viral persistence, providing a new strategy to improve immunotherapy and vaccine responses against human viral diseases.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Atea Pharmaceuticals Reports Positive Proof of Concept Clinical Data With AT-527 for the Treatment of Chronic Hepatitis C

Atea Pharmaceuticals Reports Positive Proof of Concept Clinical Data With AT-527 for the Treatment of Chronic Hepatitis C | Hepatitis C New Drugs Review | Scoop.it

Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the development of next-generation therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections, today reported positive data from its ongoing clinical trial of AT-527 in patients with GT-1b and GT-3 HCV infection. The company will present the data today at The International Liver Congress™ 2018 sponsored by the European Association for the Study of the Liver taking place in Paris, France.   

Krishan Maggon 's insight:
  • AT-527 is a novel pan-genotypic purine nucleotide prodrug NS5B polymerase inhibitor which has been safe and well tolerated in this ongoing multiple part trial
     
  • AT-527 exhibits potent antiviral activity in genotype (GT)-1b and GT-3 hepatitis C virus (HCV) infected patients with once-daily (QD) dosing of 550 mg for 7-days
     
  • Preliminary data suggest that AT-527 has potent and equivalent antiviral activity in both cirrhotic and non-cirrhotic (NC) HCV-infected patients
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Evaluation of the Xpert® HCV Viral Load Fingerstick point-of-care assay | The Journal of Infectious Diseases | Oxford Academic

Evaluation of the Xpert® HCV Viral Load Fingerstick point-of-care assay | The Journal of Infectious Diseases | Oxford Academic | Hepatitis C New Drugs Review | Scoop.it
Abstract. Point-of-care hepatitis C virus (HCV) RNA testing is advantageous enabling diagnosis of active infection in a single visit. This study evaluated the
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C: A novel point-of-care assay

Hepatitis C: A novel point-of-care assay | Hepatitis C New Drugs Review | Scoop.it
One of the major challenges identified by the WHO in efforts to eradicate the hepatitis C virus (HCV) is the diagnosis of chronic cases that are generally asymptomatic. Major progress is required for new diagnostic technique
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Characterization of Demographics and NS5A Genetic Diversity for HCV Genotype 4‐Infected Patients with or without Cirrhosis Treated with Ombitasvir/Paritaprevir/Ritonavir - Schnell - - Journal of Vi...

Characterization of Demographics and NS5A Genetic Diversity for HCV Genotype 4‐Infected Patients with or without Cirrhosis Treated with Ombitasvir/Paritaprevir/Ritonavir - Schnell - - Journal of Vi... | Hepatitis C New Drugs Review | Scoop.it

Abstract

Hepatitis C virus (HCV) genotype 4 (GT4) is genetically diverse with 17 confirmed and 4 provisional subtypes. In this report, HCV GT4‐infected patient samples from Phase 2/3 clinical studies were analyzed to characterize global demographics and genetic diversity of GT4 infection among patients treated with ombitasvir (OBV, NS5A inhibitor) plus paritaprevir/r (NS3/4A inhibitor co‐dosed with ritonavir). Among 17 subtypes isolated from GT4‐infected patients in the PEARL‐I and AGATE‐I studies, subtype prevalence by country of enrollment and country of origin suggested that subtypes 4a and 4d were likely circulating in Europe, while heterogeneous GT4 subtypes and a portion of GT4a detected in European and North American countries were likely due to immigration of HCV‐infected patients from Africa. The distributions of birth cohort and race were also significantly different across GT4 subtypes 4a, 4d, and non‐4a/4d. In addition, phylogenetic analyses of NS5A sequences revealed clustering within subtype 4a which segregated by the patient‐reported country of origin and presence of the L30R/S polymorphism. HCV NS5A sequences derived from GT4a‐infected patients who originated from Europe and the United States clustered separately from sequences derived from patients who originated from Egypt, suggesting that genetically distinct strains of subtype 4a may be circulating globally. Finally, NS5A baseline polymorphisms were frequently detected at amino acid positions of interest for the inhibitor‐class and OBV retained activity against 37 of 39 NS5A GT4 clinical isolates, with no impact on treatment outcome in the PEARL‐I and AGATE‐I studies.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals | Hepatitis C New Drugs Review | Scoop.it
They say (who are they anyway?) "If it seems to good to be true it probably is". When it comes to generic Hepatitis C medication some peopl
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Evaluation of the Xpert® HCV Viral Load Fingerstick point-of-care assay | The Journal of Infectious Diseases | Oxford Academic

Evaluation of the Xpert® HCV Viral Load Fingerstick point-of-care assay | The Journal of Infectious Diseases | Oxford Academic | Hepatitis C New Drugs Review | Scoop.it
Abstract. Point-of-care hepatitis C virus (HCV) RNA testing is advantageous enabling diagnosis of active infection in a single visit. This study evaluated the
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Oncotarget | Unbiased compound-protein interface mapping and prediction of chemoresistance loci through forward genetics in haploid stem cells

Oncotarget | Unbiased compound-protein interface mapping and prediction of chemoresistance loci through forward genetics in haploid stem cells | Hepatitis C New Drugs Review | Scoop.it
Unbiased compound-protein interface mapping and prediction of chemoresistance loci through forward genetics in haploid stem cells...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A Gathering Storm: Opioid, Heroin Addiction, and the Spread of Hepatitis C « Al D. Rodriguez Liver Foundation

A Gathering Storm: Opioid, Heroin Addiction, and the Spread of Hepatitis C « Al D. Rodriguez Liver Foundation | Hepatitis C New Drugs Review | Scoop.it
A New York Post article about an unsafe “pizza joint manager” — who was reported to have sparked hepatitis C scare — made a few rounds on the panicked social media circuit earlier this year. The Post alleged that the Indiana restaurant worker, who is infected with hepatitis C virus (HCV), was busted for heroin use on the job. The restaurant was sanitized following the arresting officer’s report that the worker was handling food without using necessary health precautions to cover her open sores. The health concern over the issue is more than warranted, given a 2017 report from the Centers for Disease Control and Prevention (CDC) linking the growing heroin epidemic and the increase in HCV infection. The CDC’s May 2017 report detailed startling coincidences between the rise of hepatitis C cases and America’s heroin epidemic. According to the report, from 2010 to 2015, the documented number of HCV cases of infection increased by 294 percent. The report noted that the rates are highest among people who’ve injected drugs. In a more recent report released in December 2017, the CDC noted that across the United States, there are serious, concurrent increases in admissions for opioid injections and acute hepatitis C infection from 2004 to 2014; 93 percent for opioid-related hospital admissions; and 133 percent for HCV infections. HCV transmission Hepatitis C is a highly contagious viral hepatitis that can be easily spread through contact with a contaminated person’s body fluid. This means that the virus can be spread through sex, childbirth (mother to child), as well as injection drug use (IDU) — which is the most common risk factor for infection according to the CDC. This helps explain why people who inject drugs (PWID) are at extreme risk for HCV infection. The majority of people with acute HCV infection do not show signs or suffer the symptoms of the infection. In cases where symptoms manifest, they appear two to six months after exposure and transmission. HCV infection symptoms include a flu-like illness accompanied by fatigue, muscle pains, stomach pain, jaundice, fever, and poor appetite. Because in many cases, HCV symptoms don’t manifest, acute HCV infection silently develops into chronic infection. It is not uncommon to have the infection for 15 years or longer, before being diagnosed. This leaves a long period of time for an undiagnosed person to unknowingly spread the disease through the sharing of needles. What the CDC reports state: Incidence of hepatitis C infections have been steadily rising since 2010 to 2015 In 2014 alone, 30,500 new cases of HCV infection was reported; 16,500 new cases were documented in 2011 The most dramatic increase of HCV infections was seen among younger Americans aged 18 to 39, from 2004 to 2014. Specifically, in translation: a 400 percent increase in HCV infection in this age group; an 817 percent increase in admissions related to injections of prescription opioid; a 600 percent increase admissions for injections related to heroin use. In summary, there is very reliable evidence that the heroin epidemic and opioid crisis has increased the incidence of HCV’s growing spread. This is a serious public health concern. The CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Director, Jonathan Mermin, warned the public that “Hepatitis C is a deadly, common, and often invisible result of America’s opioid crisis.” “By testing people who inject drugs for hepatitis C infection, treating those who test positive, and preventing new transmissions, we can mitigate some of the effects of the nation’s devastating opioid crisis and save lives,” Mermin added. ADRLF encourages you to pay close attention to this growing two-fold crisis, through vigilant awareness, prevention, and treatment — and by helping us to convey this important message to your communities, near and far; particularly the youth. To learn more about the CDC report, check out these resources: Increase in hepatitis C infections linked to worsening opioid crisis Viral Hepatitis Article for the Hepatitis Awareness Month in Morbidity and Mortality Weekly Report To learn more about hepatitis C, read on:
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis | BMC Infectious Diseases | Full Text

Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis | BMC Infectious Diseases | Full Text | Hepatitis C New Drugs Review | Scoop.it
Research article Open Access Open Peer Review This article has Open Peer Review reports available. How does Open Peer Review work? Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis Leire Pérez-Latorre1, 2Email author, Matilde Sánchez-Conde3, Pilar Miralles1, 2, Juan Carlos López1, 2, Francisco Parras1, 2, Francisco Tejerina1, 2, Teresa Aldámiz-Echevarría1, 2, Ana Carrero1, 2, Cristina Díez1, 2, Margarita Ramírez1, 2, Isabel Gutiérrez1, 2, José María Bellón2, Rafael Bañares2, 4, 5, 6 and Juan Berenguer1, 2Email authorView ORCID ID profile BMC Infectious DiseasesBMC series – open, inclusive and trusted201818:170 https://doi.org/10.1186/s12879-018-3067-z ©  The Author(s). 2018 Received: 8 August 2017 Accepted: 26 March 2018 Published: 11 April 2018 Open Peer Review reports

 

Abstract Background Little is known about the utility of transient elastography (TE) for assessing the prognosis of patients with decompensated cirrhosis (DC). Methods We analyzed HIV/HCV-coinfected patients with DC who underwent TE as part of their routine follow-up between 2006 and 2015. We also calculated the liver stiffness spleen diameter-to-platelet score (LSPS), FIB-4 index, albumin, MELD score, and Child-Pugh score. The primary outcome was death. Results The study population comprised 65 patients. After a median follow-up of 32 months after the first TE, 17 patients had received anti-HCV therapy and 31 patients had died. The highest area under the receiver operating characteristic curve (AUROC) value for prediction of death was observed with albumin (0.695), followed by Child-Pugh score (0.648), both with P values < .05. Lower AUROC values were observed with MELD score (0.633), TE (0.618), LSPS score (0.595), and FIB-4 (0.569), all with P values > .05. In the univariate Cox regression analysis, albumin, FIB-4, Child-Pugh score, and MELD score, but not TE, were associated with death. In the multivariate analysis, albumin and Child-Pugh score were the only baseline variables associated with death. Conclusions Our results suggest that TE is not useful for assessing the prognosis of HIV-infected patients with decompensated HCV-related cirrhosis. Albumin concentration and Child-Pugh scores were the most consistent predictors of death in this population group.

 

Keywords Transient elastographyLiver stiffnessLiver fibrosisFibroScanCoinfectionHIV infectionHepatitis C

 

Key points Transient elastography was not useful for assessment of the prognosis of HIV-infected patients with decompensated HCV-related cirrhosis. Serum albumin concentration and Child-Pugh score were the most consistent predictors of death in this population group. Background Chronic hepatitis C is more frequent and progresses more quickly in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) than in patients infected solely by HCV. In addition, progression to liver cirrhosis and decompensated liver disease is faster among the former [1].

 

 

 

 

 

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Scotland: Direct-acting antiviral agent therapy reduces the burden of HCV-related decompensated cirrhosis

Scotland: Direct-acting antiviral agent therapy reduces the burden of HCV-related decompensated cirrhosis | Hepatitis C New Drugs Review | Scoop.it
Two presentations given this week at The International Liver Congress 2018 in Paris, France illustrate the impact that DAAs can have in averting HCV-related liver disease, and reducing the clinical and economic burden of ...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C: What Stands in the Way of Elimination? | AbbVie

Hepatitis C: What Stands in the Way of Elimination? | AbbVie | Hepatitis C New Drugs Review | Scoop.it
The World Health Organization set a goal of eliminating viral hepatitis by 2030. What are the barriers to achieving this for hepatitis C? Four experts weigh in.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

WHO | Hepatitis C: simplified curative treatments can drive global scale-up

WHO | Hepatitis C: simplified curative treatments can drive global scale-up | Hepatitis C New Drugs Review | Scoop.it
Access to hepatitis C curative therapy is increasing, with simplified and more affordable treatments becoming more readily available to save lives and accelerate global scale-up.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids - RSC ...

Enhanced dispersive solid phase extraction assisted by cloud point strategy prior to fluorometric determination of anti-hepatitis C drug velpatasvir in pharmaceutical tablets and body fluids - RSC ... | Hepatitis C New Drugs Review | Scoop.it
An innovative spectrofluorometric method was developed for the analysis of a recently FDA approved anti-hepatitis C velpatasvir (VELP). The developed method was relied on dispersive solid phase extraction (dSPE) using synergistic effect of reduced graphene oxide (RGO) and cobalt hydroxide nanoparticles (CHNPs) in a
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study

Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study | Hepatitis C New Drugs Review | Scoop.it
Point-of-care hepatitis C virus (HCV) RNA testing offers an advantage over antibody
testing (which only indicates previous exposure), enabling diagnosis of active infection
in a single visit. In this study, we evaluated the performance of the Xpert HCV Viral
Load assay with venepuncture and finger-stick capillary whole-blood samples.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The link between hepatitis C virus and diabetes mellitus: Improvement in insulin resistance after eradication of hepatitis C virus - Hum - 2018 - Clinical Liver Disease - Wiley Online Library

The link between hepatitis C virus and diabetes mellitus: Improvement in insulin resistance after eradication of hepatitis C virus - Hum - 2018 - Clinical Liver Disease - Wiley Online Library | Hepatitis C New Drugs Review | Scoop.it
Abstract Watch a video presentation of this article Watch the interview with the author Abbreviations AKT protein kinase B ER endoplasmic reticulum HbA1c hemoglobin A1c HCV hepatitis C virus HOMA2‐IR Homeostatic Model Assessment‐Insulin Resistance IRS‐1 insulin receptor substrate 1 ROS reactive...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Evolution of Resistance-Associated Variants of All-Oral Direct-Acting Antiviral Therapy of Hepatitis C in a Clinical Setting

Evolution of Resistance-Associated Variants of All-Oral Direct-Acting Antiviral Therapy of Hepatitis C in a Clinical Setting | Hepatitis C New Drugs Review | Scoop.it
Because of the high variability of Hepatitis C virus (HCV), it might be important to characterize in vivo the evolution of resistance-associated mutations (RAVs) to direc..
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Host-targeting therapies for hepatitis C virus infection: current developments and future applications - Emilie Crouchet, Florian Wrensch, Catherine Schuster, Mirjam B. Zeisel, Thomas F. Baumert, 2018

Host-targeting therapies for hepatitis C virus infection: current developments and future applications - Emilie Crouchet, Florian Wrensch, Catherine Schuster, Mirjam B. Zeisel, Thomas F. Baumert, 2018 | Hepatitis C New Drugs Review | Scoop.it

Abstract

Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have undergone a revolution with the approval of multiple direct-acting antivirals (DAAs), which enable interferon-free treatments with considerable improvement of sustained virologic response in patients. Today, DAAs have become the standard of care for HCV therapy. However, several limitations remain, which include access to therapy, treatment failure in a subset of patients and persistent risk of HCC development following cure in patients with advanced fibrosis. By targeting conserved host proteins involved in the HCV life cycle, host-targeting agents (HTAs) offer opportunities for pan-genotypic antiviral approaches with a high barrier to drug resistance. Moreover, when applied in combination with DAAs, HTAs could improve the management of difficult-to-treat patients by acting through a complementary mechanism of action. In this review, we summarize the different HTAs evaluated in preclinical and clinical development and discuss their potential role for anti-HCV therapies.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Next-Generation Sequencing of Hepatitis C Virus (HCV) Mixed-Genotype Infections in Anti-HCV-Negative Blood Donors

Next-Generation Sequencing of Hepatitis C Virus (HCV) Mixed-Genotype Infections in Anti-HCV-Negative Blood Donors | Hepatitis C New Drugs Review | Scoop.it
The infection with more than one hepatitis C virus (HCV) genotype especially in subjects with a high risk of multiple HCV exposures has been demonstrated. The role of HCV mixed-genotype infectio
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Global HCV Elimination Targets and Challenges: An Interview with Andrew Hill | Treatment Action Group

Global HCV Elimination Targets and Challenges: An Interview with Andrew Hill | Treatment Action Group | Hepatitis C New Drugs Review | Scoop.it
By Bryn Gay & Annette Gaudino Are we on track with WHO targets[1,2] to eliminate the hepatitis C virus (HCV) by 2030? Andrew Hill, Senior Research Fellow, Liverpool University unveils powerful research that compares 91 countries’ data on HCV prevalence, diagnosis, treatment, and income level.
more...
No comment yet.